James K Liao

List of Publications by Year
in descending order

106	15,916	36303	33894
papers	citations	51 h-index	99 g-index

107	107	107	15994
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Emerging views of statin pleiotropy and cholesterol lowering. Cardiovascular Research, 2022, 118, 413-423.	3.8	54
2	Rho Kinase regulates neutrophil NET formation that is involved in UVB-induced skin inflammation. Theranostics, 2022, 12, 2133-2149.	10.0	10
3	SALADâ€BAAR : A numerical risk score for hospital admission or emergency department presentation in ambulatory patients with cardiovascular disease. Clinical Cardiology, 2021, 44, 193-199.	1.8	1
4	Increase in Blood-Brain Barrier (BBB) Permeability Is Regulated by MMP3 via the ERK Signaling Pathway. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-14.	4.0	19
5	Challenging Statin Pleiotropy: Preeclampsia. Circulation, 2021, 144, 680-683.	1.6	5
6	Vascular Stiffening Mediated by Rhoâ€Associated Coiledâ€Coil Containing Kinase Isoforms. Journal of the American Heart Association, 2021, 10, e022568.	3.7	4
7	A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. Translational Stroke Research, 2020, 11, 365-376.	4.2	22
8	Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. Expert Opinion on Therapeutic Targets, 2020, 24, 47-62.	3.4	25
9	Community Health Workers Reduce Rehospitalizations and Emergency Department Visits for Low-Socioeconomic Urban Patients With Heart Failure. Critical Pathways in Cardiology, 2020, 19, 139-145.	0.5	4
10	Regulator of Gâ€Protein Signaling 5 Maintains Brain Endothelial Cell Function in Focal Cerebral Ischemia. Journal of the American Heart Association, 2020, 9, e017533.	3.7	12
11	Serine-threonine kinase ROCK2 regulates germinal center B cell positioning and cholesterol biosynthesis. Journal of Clinical Investigation, 2020, 130, 3654-3670.	8.2	26
12	Association of Rising Violent Crime With Blood Pressure and Cardiovascular Risk: Longitudinal Evidence From Chicago, 2014â€“2016. American Journal of Hypertension, 2019, 32, 1192-1198.	2.0	15
13	Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke, 2019, 50, 738-744.	2.0	40
14	Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism. Journal of Hypertension, 2019, 37, 1083-1095.	0.5	9
15	The Pleiotropic Effects of Statins â€“ From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. Current Vascular Pharmacology, 2019, 17, 222-232.	1.7	54
16	Tumor necrosis factor-Î± levels and non-surgical bleeding in continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2018, 37, 107-115.	0.6	53
17	The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 471-481.	2.9	86
18	Neuroprotection Mediated by Upregulation of Endothelial Nitric Oxide Synthase in Rho-Associated, Coiled-Coil-Containing Kinase 2 Deficient Mice. Circulation Journal, 2018, 82, 1195-1204.	1.6	20

#	Article	IF	Citations
19	ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). Blood, 2018, 132, 1739-1739.	1.4	2
20	Pleiotropic Effects of Statins on the Cardiovascular System. Circulation Research, 2017, 120, 229-243.	4.5	808
21	Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets. Cardiovascular Research, 2017, 113, 1307-1317.	3.8	22
22	Cardiology Consultation in the Emergency Department Reduces Re-hospitalizations for Low-Socioeconomic Patients with Acute Decompensated Heart Failure. American Journal of Medicine, 2017, 130, 1112.e17-1112.e31.	1.5	13
23	ROCK as a therapeutic target for ischemic stroke. Expert Review of Neurotherapeutics, 2017, 17, 1167-1177.	2.8	44
24	RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke, 2017, 48, 187-194.	2.0	86
25	Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. JCI Insight, 2017, 2, .	5.0	55
26	Rho Kinases and Cardiac Remodeling. Circulation Journal, 2016, 80, 1491-1498.	1.6	95
27	MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation. Vascular Pharmacology, 2016, 84, 67-73.	2.1	8
28	Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. Circulation, 2016, 134, 141-152.	1.6	127
29	Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Scientific Reports, 2016, 6, 24578.	3.3	32
30	Relative Lack of Culprit and Obstructive Coronary Lesions in Patients With Acute Ischemic Stroke and Elevated Cardiac Troponin. Circulation, 2016, 133, 1228-1229.	1.6	3
31	RhoA/Rho-Associated Kinase as Marker of Cardiovascular Health. , 2016, , 739-769.		0
32	ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L736-L746.	2.9	25
33	MnTBAP stimulates angiogenic functions in endothelial cells through mitofusin-1. Vascular Pharmacology, 2015, 72, 163-171.	2.1	9
34	Exogenous nitric oxide inhibits Rho-associated kinase activity in patients with angina pectoris: a randomized controlled trial. Hypertension Research, 2015, 38, 485-490.	2.7	5
35	Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression. Journal of Molecular and Cellular Cardiology, 2015, 79, 180-186.	1.9	12
36	The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis. Pharmacological Reviews, 2015, 67, 103-117.	16.0	161

#	Article	IF	Citations
37	RhoA/Rho-Associated Kinase as Marker of Cardiovascular Health. , 2015, , 1-31.		0
38	Interventional Transcatheter Closure Ameliorates the Leukocyte Rho Kinase Activities among Patients with Patent Ductus Arteriosus. Acta Cardiologica Sinica, 2015, 31, 494-9.	0.2	0
39	Gene variations of ROCKs and risk of ischaemic stroke: the Women's Genome Health Study. Clinical Science, 2014, 126, 829-835.	4.3	14
40	Potential serum biomarkers in the pathophysiological processes of stroke. Expert Review of Neurotherapeutics, 2014, 14, 173-185.	2.8	41
41	Evidence of pleiotropy by statins: Leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. International Journal of Cardiology, 2014, 176, 250-253.	1.7	4
42	Critical Role of Exogenous Nitric Oxide in ROCK Activity in Vascular Smooth Muscle Cells. PLoS ONE, 2014, 9, e109017.	2.5	21
43	A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. International Journal of Cardiology, 2013, 167, 2813-2819.	1.7	16
44	Statins Exert the Pleiotropic Effects Through Small GTP-Binding Protein Dissociation Stimulator Upregulation With a Resultant Rac1 Degradation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1591-1600.	2.4	73
45	FHL2 prevents cardiac hypertrophy in mice with cardiacâ€specific deletion of ROCK2. FASEB Journal, 2013, 27, 1439-1449.	0.5	82
46	Linking endothelial dysfunction with endothelial cell activation. Journal of Clinical Investigation, 2013, 123, 540-541.	8.2	333
47	Inhibition of Rho-kinase attenuates endothelialâ€“leukocyte interaction during ischemiaâ€“reperfusion injury. Vascular Medicine, 2012, 17, 379-385.	1.5	19
48	Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina. Atherosclerosis, 2012, 221, 521-526.	0.8	30
49	Increased Rho kinase activity in congestive heart failure. European Journal of Heart Failure, 2012, 14, 965-973.	7.1	40
50	Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends in Pharmacological Sciences, 2011, 32, 167-173.	8.7	139
51	Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. Journal of Hypertension, 2011, 29, 373-379.	0.5	44
52	Fingolimod provides longâ€term protection in rodent models of cerebral ischemia. Annals of Neurology, 2011, 69, 119-129.	5.3	249
53	Squalene Synthase Inhibitor Lapaquistat Acetate. Circulation, 2011, 123, 1925-1928.	1.6	21
54	Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Current Opinion in Pharmacology, 2010, 10, 116-121.	3.5	53

#	Article	IF	Citations
55	Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. Journal of Clinical Investigation, 2010, 120, 3280-3295.	8.2	206
56	Response to Letters Regarding Article, â€œEvidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammationâ€• Circulation, 2009, 120, .	1.6	2
57	Evidence for Statin Pleiotropy in Humans. Circulation, 2009, 119, 131-138.	1.6	208
58	Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Research, 2009, 1257, 89-93.	2.2	48
59	Comparison of Effects of Rosuvastatin (10 mg) Versus Atorvastatin (40 mg) on Rho Kinase Activity in Caucasian Men With a Previous Atherosclerotic Event. American Journal of Cardiology, 2009, 103, 437-441.	1.6	69
60	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Current Atherosclerosis Reports, 2009, 11, 243-244.	4.8	13
61	Genetically elevated C-reactive protein and ischemic vascular disease. Current Atherosclerosis Reports, 2009, 11, 245-245.	4.8	7
62	Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis, 2009, 205, 517-521.	0.8	119
63	Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease. Current Pharmaceutical Design, 2009, 15, 3108-3115.	1.9	100
64	Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine, 2008, 14, 37-44.	6.7	522
65	Deficiency of ROCK1 in bone marrowâ€derived cells protects against atherosclerosis in LDLR ^{â^'/â^'} mice. FASEB Journal, 2008, 22, 3561-3570.	0.5	67
66	Is statin discontinuation an option in patients who have had a stroke?. Nature Clinical Practice Neurology, 2008, 4, 18-19.	2.5	0
67	A Method for Measuring Rho Kinase Activity in Tissues and Cells. Methods in Enzymology, 2008, 439, 181-189.	1.0	53
68	ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. Journal of Clinical Investigation, 2008, 118, 1632-1644.	8.2	152
69	Secondary Prevention of Stroke and Transient Ischemic Attack. Circulation, 2007, 115, 1615-1621.	1.6	53
70	Rho Kinase (ROCK) Inhibitors. Journal of Cardiovascular Pharmacology, 2007, 50, 17-24.	1.9	344
71	Roles of Rho-Associated Kinase and Oxidative Stress in the Pathogenesis of Aortic Stiffness. Journal of the American College of Cardiology, 2007, 49, 698-705.	2.8	83
72	Increased Rho Kinase Activity in a Taiwanese Population With Metabolic Syndrome. Journal of the American College of Cardiology, 2007, 49, 1619-1624.	2.8	93

#	Article	IF	Citations
73	Statins. , 2007, , 1668-1673.		0
74	Steroid Hormones. , 2007, , 1674-1681.		0
75	Safety and Efficacy of Statins in Asians. American Journal of Cardiology, 2007, 99, 410-414.	1.6	218
76	Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?. Current Atherosclerosis Reports, 2007, 9, 384-388.	4.8	5
77	Requirement of Rac1 in the development of cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7432-7437.	7.1	268
78	Physiological role of ROCKs in the cardiovascular system. American Journal of Physiology - Cell Physiology, 2006, 290, C661-C668.	4.6	339
79	Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery Disease. Circulation Research, 2006, 99, 1426-1432.	4.5	155
80	Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2005, 96, 24-33.	1.6	243
81	Decreased Perivascular Fibrosis but Not Cardiac Hypertrophy in ROCK1 +/â^' Haploinsufficient Mice. Circulation, 2005, 112, 2959-2965.	1.6	195
82	Rho GTPases, Statins, and Nitric Oxide. Circulation Research, 2005, 97, 1232-1235.	4.5	434
83	Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection. Stroke, 2005, 36, 2251-2257.	2.0	351
84	PLEIOTROPIC EFFECTS OF STATINS. Annual Review of Pharmacology and Toxicology, 2005, 45, 89-118.	9.4	1,574
85	Acute augmentation of cerebral blood flow by rho-kinase inhibitors in focal cerebral ischemia is dependent on endothelial nitric oxide synthase. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S3-S3.	4.3	0
86	Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1842-1847.	2.4	312
87	Statin Therapy for Cardiac Hypertrophy and Heart Failure. Journal of Investigative Medicine, 2004, 52, 248-253.	1.6	45
88	Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy. Circulation, 2003, 108, 839-843.	1.6	387
89	Long-term statin use and psychological well-being. Journal of the American College of Cardiology, 2003, 42, 690-697.	2.8	121
90	Role of statin pleiotropism in acute coronary syndromes and stroke. International Journal of Clinical Practice, Supplement, 2003, , 51-7.	0.3	6

#	Article	IF	Citations
91	Rho-Kinase Mediates Hypoxia-Induced Downregulation of Endothelial Nitric Oxide Synthase. Circulation, 2002, 106, 57-62.	1.6	459
92	Statins and ischemic stroke. Atherosclerosis Supplements, 2002, 3, 21-25.	1.2	16
93	Beyond lipid lowering: the role of statins in vascular protection. International Journal of Cardiology, 2002, 86, 5-18.	1.7	241
94	Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation, 2002, 110, 285-288.	8.2	327
95	Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation, 2002, 110, 285-288.	8.2	210
96	Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation, 2001, 108, 1429-1437.	8.2	429
97	Endothelial Nitric Oxide Synthase-Dependent Cerebral Blood Flow Augmentation by <scp>L</scp>-Arginine After Chronic Statin Treatment. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 709-717.	4.3	134
98	Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H2649-H2657.	3.2	82
99	Estrogens and Glucocorticoids Inhibit Endothelial Vascular Cell Adhesion Molecule-1 Expression by Different Transcriptional Mechanisms. Circulation Research, 2000, 87, 19-25.	4.5	171
100	3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27. Journal of Biological Chemistry, 1999, 274, 21926-21931.	3.4	352
101	The inhibition of endothelial activation by unsaturated fatty acids. Lipids, 1999, 34, S191-S194.	1.7	34
102	Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors. Circulation, 1998, 97, 1129-1135.	1.6	1,736
103	Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase. Journal of Biological Chemistry, 1998, 273, 24266-24271.	3.4	941
104	Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase. Journal of Biological Chemistry, 1997, 272, 31725-31729.	3.4	354
105	Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase. Journal of Biological Chemistry, 1995, 270, 319-324.	3.4	473
106	ROCK Isoforms ROCK 1 and ROCK 2 are Critical for the Development of Pulmonary Fibrosis in Several Different Cell Specific Mechanisms. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	1